Name: SILEXION THERAPEUTICS CORP (SLXN) Stock
Brand: SILEXION THERAPEUTICS CORP
Rating: 4.5 (3 reviews)

SLXN Latest News, Press Relases and Analysis

All

Press Releases

25 days ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

a month ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

a month ago - By: Benzinga - Mentions: PRPH COSM ADXN ISPC ...

12 Health Care Stocks Moving In Friday's Intraday Session

a month ago - By: Benzinga

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

a month ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

a month ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

2 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

2 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

2 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

3 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

3 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

4 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

5 months ago - By: Yahoo Finance - Mentions: CNC EQIX CRM

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

5 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

5 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

6 months ago - By: Silexion Therapeutics Corp

SILEXION THERAPEUTICS CORP (SLXN) Stock News

SLXN Latest News, Press Relases and Analysis

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

12 Health Care Stocks Moving In Friday's Intraday Session

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update